poractant alfa

(redirected from Curosurf)

poractant alfa

 [por-ak´tant al´fah]
an extract of porcine lung surfactant administered by instillation via the endotracheal tube in treatment of respiratory distress syndrome of the newborn.

poractant alfa

/por·ac·tant al·fa/ (por-ak´tant al´fah) an extract of porcine lung surfactant used in the treatment of respiratory distress syndrome of the newborn.

poractant alfa

a lung surfactant extract.
indication It is used in the treatment (rescue) of respiratory distress syndrome in premature infants.
contraindication None is currently known.
adverse effects Concurrent illnesses that have occurred during treatment with this drug include pulmonary air leaks, pulmonary interstitial emphysema, apnea, pulmonary hemorrhage, patent ductus arteriosus, intracranial hemorrhage, severe intracranial hemorrhage, necrotizing enterocolitis, posttreatment sepsis, and posttreatment infection. Adverse effects include bradycardia, oxygen desaturation, pallor, vasoconstriction, hypotension, and hypertension.
References in periodicals archive ?
Curosurf is a natural surfactant obtained from pig lungs, containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid) and approximately 1% hydrophobic proteins with molecular weight SP - B (surfactant protein B) and SP - C (surfactant protein C).
In order to assist prevention of high infant mortality, Help the Children - SKD has decided to grant 775 Curosurf packages.
A statistically significant difference was found between the study and control groups in terms of usage of Curosurf and Survanta (p=0.
In addition, Chiesi is the licensor of two of Cornerstone's key products: Curosurf and Bethkis.
M2 PHARMA-January 27, 2012-Analysis unveils positive effects of Cornerstone's CUROSURF in neonatal RDS(C)2012 M2 COMMUNICATIONS
La distribucion del uso de los surfactantes en la poblacion fue la siguiente: 26 pacientes fueron tratados con Curosurf en presentaciones de 1,5 o 3 ml, 39 con survanta en presentaciones de 4 u 8 ml y 14 pacientes recibieron infarsurf en presentaciones de 3 o 6 ml.
The transaction led to two important events: Cornerstone was conferred the responsibility for distributing Curosurf in USA and as a result, Chiesi made its direct entry into the American market.
The biological surfactant preparation Curosurf (poractant alfa) was derived from minced porcine lung extracts, and its indications followed similar risk profiles as noted in the biologicals above.
In 2000, a randomized, comparison study of prophylactic use of lung surfactants in the UK between a pumactant (a synthetic surfactant used exclusively in the UK) and Curosurf (poractant alfa) was halted half way through because of a mortality difference.
Along with its own line of generic products, DEY markets four brands: DuoNeb (albuterol sulfate and ipratropium bromide) Inhalation Solution for chronic obstructive pulmonary disease (COPD), AccuNeb (albuterol sulfate) Inhalation Solution for pediatric asthma, EpiPen (epinephrine) Auto-Injector for anaphylaxis, and Curosurf (poractant alpha) Intratracheal Suspension for infant respiratory distress syndrome.
In Turkey, only Survanta and Curosurf which are natural surfactant preparations are available.
5 December 2011 - ONY Inc, the producer of Infasurf which is used to treat premature infants against Respiratory Distress Syndrome, filed a lawsuit against Cornerstone Therapeutics (NASDAQ:CRTX) and its parent firm, Chiesi Farmaceutici SpA, of providing manipulated data to claim the use of its competing drug, Curosurf, leads to lower mortality rates.